These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 28346237)

  • 1. Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
    Banini BA; Sanyal AJ
    Curr Opin Gastroenterol; 2017 May; 33(3):134-141. PubMed ID: 28346237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future therapy for non-alcoholic fatty liver disease.
    Issa D; Patel V; Sanyal AJ
    Liver Int; 2018 Feb; 38 Suppl 1():56-63. PubMed ID: 29427492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and future pharmacological therapies for NAFLD/NASH.
    Sumida Y; Yoneda M
    J Gastroenterol; 2018 Mar; 53(3):362-376. PubMed ID: 29247356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE; Rinella ME
    Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Non-alcoholic fatty liver disease and type 2 diabetes mellitus. II. Treatment].
    Pár A; Wittmann I; Pár G
    Orv Hetil; 2022 May; 163(22):855-862. PubMed ID: 35895614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State of the art: treatment of nonalcoholic steatohepatitis.
    Pearlman M; Loomba R
    Curr Opin Gastroenterol; 2014 May; 30(3):223-37. PubMed ID: 24717764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials.
    An J; Sohn JH
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S268-S275. PubMed ID: 36537018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease: new treatments.
    Hardy T; Anstee QM; Day CP
    Curr Opin Gastroenterol; 2015 May; 31(3):175-83. PubMed ID: 25774446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
    Stein LL; Dong MH; Loomba R
    Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
    Rotman Y; Sanyal AJ
    Gut; 2017 Jan; 66(1):180-190. PubMed ID: 27646933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: new treatments in non-alcoholic fatty liver disease.
    Townsend SA; Newsome PN
    Aliment Pharmacol Ther; 2017 Sep; 46(5):494-507. PubMed ID: 28677333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis].
    Heebøll S; Kazankov K; Poulsen MK; Vilstrup H; Grønbæk H
    Ugeskr Laeger; 2012 Feb; 174(8):488-90. PubMed ID: 22348670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
    Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.